文献速递妇科产科

有乳腺癌病史女性使用阴道雌激素治疗绝经泌尿生殖综合征的安全性

Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer.
PubMed 文献 · Obstet Gynecol · 2023-08-03

基于美国大型索赔数据库的队列研究,纳入乳腺癌诊断后5年内确诊绝经泌尿生殖综合征的女性,比较接受阴道雌激素治疗者与未接受者的乳腺癌复发风险。结果显示两组复发风险相当,任何雌激素受体状态(风险比1.03,95%CI 0.91-1.18)和雌激素受体阳性状态(风险比0.94,95%CI 0.77-1.15)分析均无显著差异。

要点

  • 有乳腺癌病史女性使用阴道雌激素治疗绝经泌尿生殖综合征,5年内乳腺癌复发风险与未使用者相当。
  • 任何雌激素受体状态分析:风险比1.03(95%CI 0.91-1.18);雌激素受体阳性状态分析:风险比0.94(95%CI 0.77-1.15)。
  • 研究基于美国索赔数据库,接受阴道雌激素者占初始队列5.0%,雌激素受体阳性亚组中占3.9%。

核心结论

  • 在有乳腺癌个人史的女性中,使用阴道雌激素治疗绝经泌尿生殖综合征未发现5年内乳腺癌复发风险增加。

研究设计与样本

  • 基于美国健康研究网络(TriNetX Diamond Network)的索赔数据分析,查询时间为2009年1月至2022年6月。
  • 队列为乳腺癌诊断后5年内确诊绝经泌尿生殖综合征的女性,排除在绝经泌尿生殖综合征诊断前3个月内接受乳房切除术、放疗或化疗的活动性疾病患者。
  • 研究队列为接受3次及以上阴道雌激素处方者,对照队列为绝经泌尿生殖综合征诊断后无任何阴道雌激素处方的乳腺癌女性,并进行倾向性匹配。
  • 对雌激素受体阳性状态进行了亚组分析(当数据可得时)。

主要发现

  • 共识别42,113例乳腺癌诊断后确诊绝经泌尿生殖综合征的女性(任何雌激素受体状态),其中5.0%接受阴道雌激素。
  • 初始队列中10,584例有雌激素受体阳性乳腺癌病史,该组中3.9%接受阴道雌激素。
  • 任何雌激素受体状态分析中,接受与未接受阴道雌激素者的乳腺癌复发风险相当(风险比1.03,95%CI 0.91-1.18)。
  • 雌激素受体阳性状态分析中,接受与未接受阴道雌激素者的乳腺癌复发风险相当(风险比0.94,95%CI 0.77-1.15)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risk of recurrence of breast cancer associated with vaginal estrogen therapy in women diagnosed with genitourinary syndrome of menopause with a history of breast cancer using a large U.S. claims database. METHODS: A U.S. health research network (TriNetX Diamond Network) was queried from January 2009 to June 2022. Our cohort consisted of women diagnosed with breast cancer within 5 years before the initial genitourinary syndrome of menopause diagnosis. Patients with active disease , defined as those undergoing mastectomy, radiation treatment, or chemotherapy within 3 months before diagnosis of genitourinary syndrome of menopause, were excluded. Recurrence was defined as mastectomy, radiation, chemotherapy, or secondary malignancy within 3 months to 5 years after the initiation of vaginal estrogen therapy for genitourinary syndrome of menopause. The study cohort included those with three or more vaginal estrogen prescriptions. The control cohort included women with breast cancer without any vaginal estrogen prescriptions after genitourinary syndrome of menopause diagnosis. Propensity matching was performed. A subanalysis by positive estrogen receptor status, when available, was performed. RESULTS: We identified 42,113 women with a diagnosis of genitourinary syndrome of menopause after breast cancer diagnosis with any estrogen receptor status, 5.0% of whom received vaginal estrogen. Of the initial cohort, 10,584 patients had a history of positive estrogen receptor breast cancer, and 3.9% of this group received vaginal estrogen. Risk of breast cancer recurrence was comparable between those who received vaginal estrogen and those who did not in both the any estrogen receptor (risk ratio 1.03, 95% CI 0.91-1.18) and positive estrogen receptor (risk ratio 0.94, 95% CI 0.77-1.15) status analyses. CONCLUSION: In a large, claims-based analysis, we did not find an increased risk of breast cancer recurrence within 5 years in women with a personal history of breast cancer who were using vaginal estrogen for genitourinary syndrome of menopause.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Agrawal P, Singh SM, Able C, et al. Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer. Obstet Gynecol. 2023. PMID: 37535961. doi:10.1097/AOG.0000000000005294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。